Kintara Therapeutics Inc ist eine Aktie aus dem Premium-Bereich von aktien.guide. Bitte anmelden, um einen Alarm für Kintara Therapeutics Inc zu aktivieren.
Kostenlos registrieren
Bitte registriere Dich kostenlos, um Kintara Therapeutics Inc zu Deinem Portfolio hinzuzufügen.
SAN DIEGO , May 14, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal third quarter ended March 31, 2024, and recent corporate developments. Recent Corporate Developments Announced that Kintara had entered into a ...
NEW YORK , April 9, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and is investigating Kintara Therapeutics, Inc. (Nasdaq: KTRA), relating to its proposed merger w...
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Kintara Therapeutics, Inc. (the “Company”) (NasdaqCM: KTRA) and TuHURA Biosciences, Inc. KSF is seeking to determine whether the merger and the process that led to it are adequate, and whether the merger is fair...
MILWAUKEE , April 3, 2024 /PRNewswire/ -- Ademi LLP is investigating Kintara (Nasdaq: KTRA) for possible breaches of fiduciary duty and other violations of law in its transaction with TuHURA. Click here to learn how to join the https://www.ademilaw.com/case/kintara-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.
Kintara Therapeutics (NASDAQ: KTRA ) stock is rocketing higher on Wednesday after the biopharmaceutical company announced plans to merge with TuHURA Biosciences . Kintara Therapeutics and TuHURA Biosciences will use an all-stock transaction to combine the two companies.
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Kintara Therapeutics, Inc. (NASDAQ: KTRA) and TuHURA Biosciences, Inc. is fair to Kintara shareholders. Halper Sadeh encourages Kintara shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@h...
TuHURA is planning to advance a single Phase 3 trial for IFx-2.0 personalized cancer vaccine as adjunctive therapy with Keytruda® in first-line therapy for advanced Merkel cell carcinoma in 2H 2024 under FDA's accelerated approval pathway $31 million subscribed financing by TuHURA in connection with the merger agreement expected to provide cash runway into late 2025 TuHURA's first-in-class bifu...
Sizing positions correctly is a cornerstone of successful investing, especially when dealing with penny stocks. The unique nature of penny stocks, with their potential for substantial gains, requires a nuanced approach to position sizing.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.